Obesity bet may drive focus on chronic segment: Alkem Labs
Alkem Labs anticipates its upcoming semaglutide launch will drive a strategic shift from acute treatments to chronic care, including diabetes and obesity. The company aims to double its chronic segment revenue in three to five years, leveraging organic growth and acquisitions. This move is expected to create a more consistent sales trajectory for Alkem.